G
G. Van Assche
Researcher at Katholieke Universiteit Leuven
Publications - 72
Citations - 3234
G. Van Assche is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Ulcerative colitis & Crohn's disease. The author has an hindex of 27, co-authored 72 publications receiving 2905 citations.
Papers
More filters
Journal ArticleDOI
Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis.
Marc Ferrante,André D'Hoore,Severine Vermeire,Steven Declerck,Maja Noman,G. Van Assche,Ilse Hoffman,Paul Rutgeerts,Freddy Penninckx +8 more
TL;DR: Coricosteroids and a restorative proctocolectomy without defunctioning ileostomy, but not IFX, are associated with an increased risk of short‐term postoperative infectious complications in patients with ulcerative colitis.
Journal ArticleDOI
The impact of major depressive disorder on the short‐ and long‐term outcome of Crohn's disease treatment with infliximab
Philippe Persoons,Severine Vermeire,Koen Demyttenaere,Benjamin Fischler,Joris Vandenberghe,L. Van Oudenhove,Marie J. Pierik,Tibor Hlavaty,G. Van Assche,Maja Noman,Paul Rutgeerts +10 more
TL;DR: This data indicates that a central nervous system disorder related to major depressive disorder may be a potential mediating role in the course of Crohn's disease.
Journal ArticleDOI
Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
TL;DR: Infliximab, the chimeric monoclonal IgG1 antibody to tumour necrosis factor, is indicated for refractory luminal and fistulizing Crohn's disease and extra‐intestinal manifestations of inflammatory bowel disease.
Journal ArticleDOI
The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study.
Ludwig Marchal,G. D'Haens,G. Van Assche,Severine Vermeire,Maja Noman,Marc Ferrante,Martin Hiele,M Bueno De Mesquita,André D'Hoore,Freddy Penninckx,Paul Rutgeerts +10 more
TL;DR: By temporarily suppressing the immune response, the anti‐tumour necrosis factor agent, infliximab, may increase the risk of peri‐operative complications.
Journal ArticleDOI
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease.
Freddy Cornillie,D. Shealy,G. D'Haens,K. Geboes,G. Van Assche,Jan Ceuppens,C. Wagner,Thomas F. Schaible,S. E. Plevy,S. R. Targan,Paul Rutgeerts +10 more
TL;DR: Anti‐TNFα therapy with infliximab is effective for Crohn’s disease and neutralizes the biological activities of TNFα, a cytokine involved in host‐defence against certain infections.